JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML [6]

Leukemia

Volumn 21, Issue 1, 2007, Pages 183-184

  Schnittger, S ^a   Bacher, U ^b   Kern, W ^a   Haferlach, C ^a   Haferlach, T ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CELL STRUCTURE; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; LETTER; LEUKEMOGENESIS; MALE; POINT MUTATION; PRIORITY JOURNAL; SEMINOMA; SIDE EFFECT; SOMATIC MUTATION;

EID: 33845526943     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404465     Document Type: Letter

References (8)

1. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25: 1434-1436.
2. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971-978.
3. Schnittger S, Bacher U, Kern W, Haferlach T, Schoch C. The role of the JAK2 mutations: A study in 1103 patients with CMPD and in 196 patients with AML. Blood 2006 (Suppl): (in press).
4. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001; 8: 189-191.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
6. Kuchenbauer FS, Susanne L, Thomas G, Gary T, David H, Torsten H et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134: 610-619.
7. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168.
8. Desta F, Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases. Leukemia 2006; 20: 547-548.